Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10155330 | 0.90 | BACE1 (0.55) | BACE1KCNH2 | |
| SCHEMBL10156073 | 0.86 | BACE1 (0.57) | BACE1KCNH2 | |
| SCHEMBL10154991 | 0.81 | BACE1 (0.47) | BACE1KCNH2 | |
| SCHEMBL10156341 | 0.80 | BACE1 (0.62) | BACE1KCNH2 | |
| SCHEMBL10155226 | 0.78 | BACE1 (0.60) | BACE1KCNH2 | |
| SCHEMBL10155686 | 0.76 | BACE1 (0.65) | BACE1KCNH2 | |
| SCHEMBL10155195 | 0.75 | BACE1 (0.56) | BACE1KCNH2 | |
| SCHEMBL10155085 | 0.75 | BACE1 (0.80) | BACE1KCNH2 | |
| SCHEMBL16472024 | 0.74 | BACE1 (0.51) | BACE1KCNH2 | |
| SCHEMBL13307061 | 0.74 | BACE1 (0.31) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20130303755-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303755-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8546380-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546380-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885KCNH2 2842/4885 |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885KCNH2 2713/4885 |
| US-20130303755-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885KCNH2 2842/4885 |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885KCNH2 2842/4885 |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885KCNH2 2842/4885 |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885KCNH2 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.